Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Since their introduction, the selective serotonin reuptake inhibitors (SSRIs) have become one of the most widely used classes of medication in psychiatry. Their popularity is based on apparent efficacy over a wide range of disorders and a favorable side-effect profile. However, as with any psychotropic medication, considerable data are required to define where a drug works and where it does not. There is now a wealth of evidence demonstrating that SSRIs may differ in their efficacy profiles in certain depressive symptoms, in different subtypes of depression, with respect to their ability to maintain efficacy over time, on broader outcomes such as quality of life, and in the consistency of the usually effective minimum therapeutic dose across the age spectrum and across indications. Although this review includes data on all SSRIs, it focuses on fluoxetine and sertraline, which in addition to being the most widely used SSRIs are also the most widely studied. The relative quantity and quality of data on these two SSRIs means that it is possible to make relatively firm inferences regarding their differential effects on affective symptoms and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Functioning and Well-being of Depressed Patients: Results From the Medical Outcomes Study
Wells, K. B. (1989) · JAMA · doi:10.1001/jama.1989.03430070062031 · Cited by 2,130
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Psychomotor symptoms of depression
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.1.4 · Cited by 662
Practice guideline for major depressive disorder in adults. American Psychiatric Association
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.1 · Cited by 226
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., & Cowen, P. J. (1996) · Psychopharmacology · doi:10.1007/bf02246410 · Cited by 122
Robert, P., Montgomery, S. A., Darcourt, G., Robert, G., Houillon, P., Bouchard, J. M., Tatossian, A., Planche, R., Bourgeois, M., Richou, H., et al. (1995) · International Clinical Psychopharmacology · doi:10.1097/00004850-199503001-00006 · Cited by 85
TOLLEFSON, G. D., GREIST, J. H., JEFFERSON, J. W., HEILIGENSTEIN, J. H., SAYLER, M. E., TOLLEFSON, S. L., & KOBACK, K. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00003 · Cited by 47
Controlling Acute Episodes of Depression
LAPIERRE, Y. D. (1991) · International Clinical Psychopharmacology · doi:10.1097/00004850-199112002-00005 · Cited by 27
Cited by
Matza, L. S., Swensen, A. R., Flood, E. M., Secnik, K., & Leidy, N. K. (2004) · Value in Health · doi:10.1111/j.1524-4733.2004.71273.x · Cited by 684
Bourin, M., Chue, P., & Guillon, Y. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00189.x · Cited by 408
Serotonergic modulation of the limbic system
Hensler, J. G. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.06.007 · Cited by 319
Selective serotonin reuptake inhibitors in affective disorders — I. Basic pharmacology
Goodnick, P. J., & Goldstein, B. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003021 · Cited by 183
Self-citationSSRIs and cognitive performance in a working sample
Wadsworth, E. J. K., Moss, S. C., Simpson, S. A., & Smith, A. P. (2005) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.725 · Cited by 54
“In part, this may be due to the differing pharmacological, and hence specific cognitive effects, or individual SSRIs (Goldstein and Goodnick, 1998; Goodnick and Goldstein, 1998).”
Metadata
- Authors
- Goodnick, P. J., & Goldstein, B. J.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1998-07
- Volume
- 12
- Issue
- 4_suppl
- Pages
- S21-S54
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1920284474
- Cited by
- 47
- References
- 8
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life. https://app.cochat.ai/papers/10.1177/0269881198012003031
- The paper
- Goodnick, P. J., & Goldstein, B. J. (1998). Selective serotonin reuptake inhibitors in affective disorders -II. Efficacy and quality of life. Journal of Psychopharmacology. https://doi.org/10.1177/0269881198012003031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.